<DOC>
	<DOCNO>NCT01276509</DOCNO>
	<brief_summary>Adults Crohn 's disease clinically active despite conventional treatment eligible study . Patients may receive one three dose PF-00547659 ( experimental drug ) placebo ( inactive drug ) . Disease activity measure every two week .</brief_summary>
	<brief_title>Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must fail intolerant antiTNFs and/or immunosuppressant ( AZA , 6MP , and/or MTX ) . hsCRP great 3mg/L Ulcerations demonstrate colonoscopy perform screen 8 week prior screen Pregnant breast feed Short bowel syndrome due multiple small bowel resection Presence stoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Crohn 's disease Safety Efficacy Pharmacokinetics Pharmacodynamics Crohn 's Disease Activity Index ( CDAI )</keyword>
</DOC>